IDO Targeting in Sarcoma: Biological and Clinical Implications.

Autor:	Nafia I; Explicyte Immuno-Oncology, Bordeaux, France., Toulmonde M; Department of Medical Oncology, Institut Bergonié, Bordeaux, France., Bortolotto D; Explicyte Immuno-Oncology, Bordeaux, France., Chaibi A; Explicyte Immuno-Oncology, Bordeaux, France., Bodet D; Explicyte Immuno-Oncology, Bordeaux, France., Rey C; Explicyte Immuno-Oncology, Bordeaux, France., Velasco V; Department of Medical Oncology, Institut Bergonié, Bordeaux, France., Larmonier CB; Department of Medical Oncology, Institut Bergonié, Bordeaux, France., Cerf L; Explicyte Immuno-Oncology, Bordeaux, France., Adam J; Department of Pathology, Gustave Roussy, Villejuif, France., Le Loarer F; Department of Medical Oncology, Institut Bergonié, Bordeaux, France., Savina A; Institut Roche, Paris, France., Bessede A; Explicyte Immuno-Oncology, Bordeaux, France., Italiano A; Department of Medical Oncology, Institut Bergonié, Bordeaux, France.; Inserm U1218, Bordeaux, France.
Jazyk:	angličtina
Zdroj:	Frontiers in immunology [Front Immunol] 2020 Mar 05; Vol. 11, pp. 274. Date of Electronic Publication: 2020 Mar 05 (Print Publication: 2020).
DOI:	10.3389/fimmu.2020.00274
Abstrakt:	Sarcomas are heterogeneous malignant mesenchymal neoplasms with limited sensitivity to immunotherapy. We recently demonstrated an increase in Kynurenine Pathway (KP) activity in the plasma of sarcoma patients treated with pembrolizumab. While the KP has already been described to favor immune escape through the degradation of L-Tryptophan and production of metabolites including L-Kynurenine, Indoleamine 2,3 dioxygenase (IDO1), a first rate-limiting enzyme of the KP, still represents an attractive therapeutic target, and its blockade had not yet been investigated in sarcomas. Using immunohistochemistry, IDO1 and CD8, expression profiles were addressed within 203 cases of human sarcomas. At a preclinical level, we investigated the modulation of the KP upon PDL1 blockade in a syngeneic model of sarcoma through mRNA quantification of key KP enzymes within the tumor. Furthermore, in order to evaluate the possible anti-tumor effect of IDO blockade in combination with PDL1 blockade, an innovative IDO inhibitor (GDC-0919) was used. Its effect was first assessed on Kynurenine to Tryptophan ratio at plasmatic level and also within the tumor. Following GDC-0919 treatment, alone or in combination with anti-PDL1 antibody, tumor growth, immune cell infiltration, and gene expression profiling were measured. IDO1 expression was observed in 39.1% of human sarcoma cases and was significantly higher in tumors with high CD8 infiltration. In the pre-clinical setting, blockade of PDL1 led to a strong anti-tumor effect and was associated with an intratumoral inflammatory cytokines signature driven by Ifng but also with a modulation of the KP enzymes including Ido1 and Ido2. IDO1 inhibition using GDC-0919 resulted in (i) a significant decrease of plasmatic Kynurenine to Tryptophan ratio and in (ii) a decrease of tumoral Kynurenine. However, GDC-0919 used alone or combined with anti-PDL1, did not show anti-tumoral activity and did not affect the tumor immune cell infiltrate. In order to elucidate the mechanism(s) underlying the lack of effect of GDC-0919, we analyzed the gene expression profile of intratumoral biopsies. Interestingly, we have found that GDC-0919 induced a downregulation of the expression of pvr and granzymes, and an upregulation of inhba and Dtx4 suggesting a potential role of the IDO pathway in the control of NK function. (Copyright © 2020 Nafia, Toulmonde, Bortolotto, Chaibi, Bodet, Rey, Velasco, Larmonier, Cerf, Adam, Le Loarer, Savina, Bessede and Italiano.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu